PVR and neoplasm: systematically summarized the important mechanisms of TIGIT in inhibiting anti-tumor immunity (43), which mainly includes the following three mechanisms: first, the PVR of tumor cells or dendritic cells binds to the TIGIT on the surface of tumor-infiltrating CD8+T cells or NK cells, directly inhibiting the activity of these two immune cells.